Clinical Trials Logo

Thyroid Diseases clinical trials

View clinical trials related to Thyroid Diseases.

Filter by:

NCT ID: NCT02973997 Completed - Clinical trials for Poorly Differentiated Thyroid Gland Carcinoma

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Start date: February 7, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab and lenvatinib work in treating patients with differentiated thyroid cancer that has spread to other places in the body or has come back and cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02966093 Completed - Clinical trials for Differentiated Thyroid Cancer (DTC)

A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China

Start date: January 11, 2017
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to compare the progression-free survival (PFS) of participants with radioiodine (131 I)-refractory differentiated thyroid cancer (DTC) and radiographic evidence of disease progression within the prior 12 months treated with lenvatinib 24 mg by continuous once daily (QD) oral dosing versus placebo.

NCT ID: NCT02951000 Completed - Thyroid Disease Clinical Trials

Platysma Trial - Platysma Suturing Versus no Sutures for Wound Closure After Primary Thyroid Surgery

Platysma
Start date: February 2016
Phase: N/A
Study type: Interventional

Influence of the platysma suture on postoperative pain and wound healing.

NCT ID: NCT02950142 Completed - Obesity Clinical Trials

Evidence-based Laboratory Test Order Sets in Primary Care

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

Cluster randomised controlled trial to evaluate what the effect is of evidence-based order sets aimed at five indications on the appropriateness of laboratory test ordering in primary care.

NCT ID: NCT02947035 Completed - Thyroid Cancer Clinical Trials

Molecular Testing to Direct Extent of Initial Thyroid Surgery

Start date: February 1, 2017
Phase: Phase 2
Study type: Interventional

The research study consists of the participant agreeing to 1) the use of preoperative molecular testing (ThyroSeq) to guide extent of initial surgery and 2) the prospective collection of medical record data related to treatment of thyroid cancer.

NCT ID: NCT02943980 Completed - Thyroid Clinical Trials

Influenced the Type of Laryngoscopy the Intraoperative Nerve Monitoring During Thyroid Surgery

LiON
Start date: January 3, 2017
Phase: N/A
Study type: Interventional

A randomized controlled prospective study of laryngoscopy and evaluation of the Intraoperative nerve monitoring during thyroid surgery comparing direct laryngoscopy and the C-MAC videolaryngoscope.

NCT ID: NCT02878044 Completed - Thyroid Cancer Clinical Trials

Shared Decision Making in Patients With Thyroid Nodules

Start date: August 18, 2016
Phase: N/A
Study type: Interventional

The objective of this project is to evaluate a treatment decision aid for patients with low risk thyroid cancer.

NCT ID: NCT02870569 Completed - Clinical trials for Differentiated Thyroid Cancer

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Start date: September 2016
Phase: Phase 2
Study type: Interventional

Donafenib for advanced 131I-refractory/resistant differentiated thyroid cancer(DTC).

NCT ID: NCT02862470 Completed - Thyroid Cancer Clinical Trials

Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients

Start date: August 5, 2016
Phase:
Study type: Observational [Patient Registry]

The investigators expected to enroll 30 patients with papillary, follicular or anaplastic thyroid cancer, and collect their urine samples before operation, immediately after operation, post-operative 3, 6 12 months. The investigators will analyze the urine exosomal proteins and probable biological markers. The investigators hope to find the prognostic biological markers via this prospective study. The investigators further hope to find newly therapeutic mechanism and medications for such patients with poorly-differentiated or anaplastic thyroid cancer.

NCT ID: NCT02856347 Completed - Clinical trials for Medullary Thyroid Cancer

Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin

CMTpostopFDOPA
Start date: March 22, 2017
Phase: N/A
Study type: Interventional

The aim of the trial is to study a radiating diagnosis agent used in post surgery when the biological assessment highlighted a residual disease. This is an inter-regional multicentric, prospective study evaluating the benefit of PET F-DOPA imaging in involved node detection compared to standard imaging assessment in patient with medullary thyroid cancer. The purpose of the study is to evaluate the impact and performance of a new PET / CT (computerized tomography ) tracer targeting dopamine receptor in patient with residual ganglionar biological disease after initial surgery of medullary thyroid cancer compared to standard imaging. Obtained data will be compared to the "gold standard" based on : - nodes cytology when they could be punctured - histology when a new surgery will be recommended - surveillance when the 2 first cases will be not applicable (imaging monitoring, evolution of thyrocalcitonin)